Dunleavy K. Next Year, When AbbVie Loses Its Exclusivity for Humira in the U.S., Nearly a Dozen Companies Will Be Ready with Biosimilars to Claim a Piece of a Lucrative Market. Of Humira’s $20.6 Million Sales in 2021, $17.3 Billion Came in the U.S. (AbbVie). Fierce Pharma; 2022. https://www.fiercepharma.com/manufacturing/abbvie-says-supply-capabilities-will-be-key-differentiator-between-humiras-biosimilar. Accessed March 9, 2023. At some …
Creating Positivity + Inspiring Others